ReviewBJUI compass2024
Fluoroquinolone resistance in urinary tract infections: Epidemiology, mechanisms of action and management strategies.
Review in BJUI compass, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 30 citations in OpenAlex.
- Impact of SGLT2 inhibitors on asymptomatic bacteriuria in T2DM: prevalence, pathogens and risk factors.Infection · 2026Article
- Antimicrobial resistance and carbapenemase production among gram-negative bacteria in a newly established hospital.Naunyn-Schmiedeberg's archives of pharmacology · 2026Article
- Nanostructured Lipid Carriers Enhance Ciprofloxacin Antibacterial Activity Through Diffusion-Controlled Release and Modulation of Bacterial Growth Kinetics.Pharmaceutics · 2026Article
- MappingAntibiotics (Basel, Switzerland) · 2026Article
- Drug Resistance Patterns and Pathogen Distribution in Patients with Urinary Tract Infection in Suzhou, China: A Five-Year Retrospective Study (2020-2024).Infection and drug resistance · 2026Article
- A Review on the Current and Future State of Urinary Tract Infection Diagnostics.International journal of molecular sciences · 2025Review
- Phenotype-genotype discordance in antimicrobial resistance profiles of Gram-negative uropathogens recovered from catheter-associated urinary tract infections in Egypt.The Journal of antimicrobial chemotherapy · 2025Article
- Characteristics of quinolone resistance in Escherichia coli isolated from wildlife in Poland.Scientific reports · 2025Article
- The Current Landscape of Antibiotic Use and Antimicrobial Resistance in Japan: Focusing on Common Infections Including Uncomplicated Urinary Tract Infection and Gonorrhea.Antibiotics (Basel, Switzerland) · 2025Review
- Challenges and Prospects for Eradication ofPathogens (Basel, Switzerland) · 2025Review
- The Rise, Fall, and Rethink of (Fluoro)quinolones: A Quick Rundown.Pathogens (Basel, Switzerland) · 2025Review
- Review
- Unraveling the Length of Hospital Stay for Patients with Urinary Tract Infections: Contributing Factors and Microbial Susceptibility.Antibiotics (Basel, Switzerland) · 2025Article
- Drug susceptibility of uropathogens isolated from patients treated at the Mazovian Specialized Hospital in Radom.Acta biochimica Polonica · 2025Article
- Article
- Fluoroquinolone Resistance inMicroorganisms · 2024Review
- Fluoroquinolone resistance in urinary tract infections: Epidemiology, mechanisms of action and management strategies.BJUI compass · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Fluoroquinolone resistance is an issue of concern amongst physicians worldwide. In urology, fluoroquinolones are often used in the treatment of acute pyelonephritis and prostatitis, as well as infections caused by multidrug-resistant pathogens. Aims: We aim to highlight the importance of antimicrobial stewardship and the need for ongoing biomedical research to discover novel agents in our losing battle against resistant pathogens. Materials and methods: In this review, we survey the literature and summarise fluoroquinolone resistance as it pertains to pyelonephritis and prostatitis, as well as alternative treatment strategies and prevention of multidrug resistance. Results: The rise of fluoroquinolone resistance in bacteria has reduced the available treatment options, often necessitating hospital admission for intravenous antibiotics, which places an additional burden on both patients and the healthcare system. Many countries such as Australia have attempted to limit fluoroquinolone resistance by imposing strict prescribing criteria, though these efforts have not been entirely successful. Solutions to overcome resistance include prevention, combination therapy and the development of novel antimicrobial agents. Conclusions: Prevention of the proliferation of resistant organisms by antimicrobial stewardship is paramount, and urologists are obliged to be aware of responsible prescribing practices such as referring to local guidelines when prescribing. By reserving fluoroquinolones for infections in which they are truly indicated and by prescribing based on both patient and local environmental factors, we can preserve this effective resource for future use.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.